JP2013508739A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508739A5 JP2013508739A5 JP2012536962A JP2012536962A JP2013508739A5 JP 2013508739 A5 JP2013508739 A5 JP 2013508739A5 JP 2012536962 A JP2012536962 A JP 2012536962A JP 2012536962 A JP2012536962 A JP 2012536962A JP 2013508739 A5 JP2013508739 A5 JP 2013508739A5
- Authority
- JP
- Japan
- Prior art keywords
- labeled
- tnfα
- tnfα drug
- amount
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 18
- 229940079593 drugs Drugs 0.000 claims 18
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 8
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 8
- 238000004164 analytical calibration Methods 0.000 claims 4
- 238000011088 calibration curve Methods 0.000 claims 4
- 108090001123 antibodies Proteins 0.000 claims 3
- 102000004965 antibodies Human genes 0.000 claims 3
- 238000001542 size-exclusion chromatography Methods 0.000 claims 3
- 239000012099 Alexa Fluor family Substances 0.000 claims 2
- 210000002966 Serum Anatomy 0.000 claims 2
- 239000000975 dye Substances 0.000 claims 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 claims 2
- 108010007562 Adalimumab Proteins 0.000 claims 1
- 102000003852 Autoantibodies Human genes 0.000 claims 1
- 108090000206 Autoantibodies Proteins 0.000 claims 1
- 229940090100 Cimzia Drugs 0.000 claims 1
- 229940073621 Enbrel Drugs 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 229940048921 Humira Drugs 0.000 claims 1
- 108010053490 Infliximab Proteins 0.000 claims 1
- 229940116176 Remicade Drugs 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
Claims (16)
- 試料中の抗TNFα薬の存在又はレベルを決定する方法であって、以下の工程:
(a)標識されたTNFαを、抗TNFα薬を有する試料と接触させて、抗TNFα薬との標識された複合体を形成する工程と;
(b)標識された複合体をサイズ排除クロマトグラフィーに付して標識された複合体をフリーの標識されたTNFαから分離し、前記標識された複合体の量及び前記フリーの標識されたTNFαの量を検出する工程と;及び
(c)工程(b)における前記標識された複合体の量及び前記フリーの標識されたTNFαの量と、既知量の抗TNFα薬の検量線とを比較し、抗TNFα薬の存在又はレベルを決定する工程と、
を含む、方法。 - 前記検量線が、前記標識されたTNFαを既知量の抗TNFα薬とインキュベートすることによって作成される、請求項1に記載の方法。
- 前記標識されたTNFαがフルオロフォア標識されたTNFαである、請求項1又は2に記載の方法。
- 前記フルオロフォアがAlexa Fluor(商標)色素である、請求項3に記載の方法。
- 前記標識された複合体が最初に溶出され、その後に前記フリーの標識されたTNFαが溶出される、請求項1〜4のいずれか一項に記載の方法。
- 試料中の抗TNFα薬に対する自己抗体の存在又はレベルを決定する方法であって、以下の工程:
(a)標識された抗TNFα薬を試料と接触させて自己抗体との標識された複合体を形成する工程と;
(b)前記標識された複合体をサイズ排除クロマトグラフィーに付して標識された複合体をフリーの標識された抗TNFα薬から分離し、前記標識された複合体の量及び前記フリーの標識された抗TNFα薬の量を検出する工程と;及び
(c)工程(b)における前記標識された複合体の量及び前記フリーの標識された抗TNFα薬の量と、既知量の自己抗体の検量線とを比較し、自己抗体の存在又はレベルを検出する工程と、
を含む、方法。 - 前記検量線が、前記標識された抗TNFα薬を自己抗体陽性血清とインキュベートすることによって作成される、請求項6に記載の方法。
- 前記自己抗体がヒト抗マウス抗体(HAMA)、ヒト抗キメラ抗体(HACA)、ヒト抗ヒト化抗体(HAHA)、及びそれらの組み合わせからなる群から選択されるメンバーである、請求項6又は7に記載の方法。
- 前記標識された抗TNFα薬がフルオロフォア標識された抗TNFα薬である、請求項6〜8のいずれか一項に記載の方法。
- 前記フルオロフォアがAlexa Fluor(商標)色素である、請求項9に記載の方法。
- 前記標識された複合体が最初に溶出され、その後に前記フリーの標識された抗TNFα薬が溶出される、請求項6〜10のいずれか一項に記載の方法。
- 前記フリーの標識された抗TNFα薬対内部標準の比を決定し、検量線から前記自己抗体のレベルを外挿するために前記比を用いる、請求項6〜11のいずれか一項に記載の方法。
- 前記試料が血清である、請求項1〜12のいずれか一項に記載の方法。
- 前記抗TNFα薬が、REMICADE(商品名)(インフリキシマブ)、ENBREL(商品名)(エタネルセプト)、HUMIRA(商品名)(アダリムマブ)、CIMZIA(商標)(セルトリズマブ ペゴル)、及びそれらの組み合わせからなる群から選択されるメンバーである、請求項1〜13のいずれか一項に記載の方法。
- 前記サイズ排除クロマトグラフィーがサイズ排除−高速液体クロマトグラフィー(SE−HPLC)である、請求項1〜14のいずれか一項に記載の方法。
- 前記試料が前記抗TNFα薬を用いた治療を受けている被験者から得られたものである、請求項1〜15のいずれか一項に記載の方法。
Applications Claiming Priority (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25504809P | 2009-10-26 | 2009-10-26 | |
US61/255,048 | 2009-10-26 | ||
US26287709P | 2009-11-19 | 2009-11-19 | |
US61/262,877 | 2009-11-19 | ||
US32463510P | 2010-04-15 | 2010-04-15 | |
US61/324,635 | 2010-04-15 | ||
US34556710P | 2010-05-17 | 2010-05-17 | |
US61/345,567 | 2010-05-17 | ||
US35126910P | 2010-06-03 | 2010-06-03 | |
US61/351,269 | 2010-06-03 | ||
US38967210P | 2010-10-04 | 2010-10-04 | |
US61/389,672 | 2010-10-04 | ||
US39358110P | 2010-10-15 | 2010-10-15 | |
US61/393,581 | 2010-10-15 | ||
PCT/US2010/054125 WO2011056590A1 (en) | 2009-10-26 | 2010-10-26 | Assays for the detection of anti-tnf drugs and autoantibodies |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015024359A Division JP5878253B2 (ja) | 2009-10-26 | 2015-02-10 | 抗tnf薬及び自己抗体の検出用アッセイ |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013508739A JP2013508739A (ja) | 2013-03-07 |
JP2013508739A5 true JP2013508739A5 (ja) | 2013-12-12 |
JP5697677B2 JP5697677B2 (ja) | 2015-04-08 |
Family
ID=43618083
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012536962A Expired - Fee Related JP5697677B2 (ja) | 2009-10-26 | 2010-10-26 | 抗tnf薬及び自己抗体の検出用アッセイ |
JP2015024359A Expired - Fee Related JP5878253B2 (ja) | 2009-10-26 | 2015-02-10 | 抗tnf薬及び自己抗体の検出用アッセイ |
JP2016012688A Expired - Fee Related JP6082831B2 (ja) | 2009-10-26 | 2016-01-26 | 抗tnf薬及び自己抗体の検出用アッセイ |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015024359A Expired - Fee Related JP5878253B2 (ja) | 2009-10-26 | 2015-02-10 | 抗tnf薬及び自己抗体の検出用アッセイ |
JP2016012688A Expired - Fee Related JP6082831B2 (ja) | 2009-10-26 | 2016-01-26 | 抗tnf薬及び自己抗体の検出用アッセイ |
Country Status (15)
Country | Link |
---|---|
US (5) | US8574855B2 (ja) |
EP (1) | EP2494352B1 (ja) |
JP (3) | JP5697677B2 (ja) |
KR (2) | KR101761541B1 (ja) |
CN (2) | CN104634955B (ja) |
AU (4) | AU2010315547C1 (ja) |
BR (1) | BR112012009855A2 (ja) |
CA (2) | CA3108458A1 (ja) |
ES (1) | ES2796530T3 (ja) |
IL (2) | IL219315B (ja) |
MX (2) | MX343328B (ja) |
NZ (3) | NZ621655A (ja) |
RU (2) | RU2015148676A (ja) |
WO (1) | WO2011056590A1 (ja) |
ZA (2) | ZA201203717B (ja) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2261230T3 (en) | 2002-09-11 | 2017-06-12 | Chugai Pharmaceutical Co Ltd | Method of Protein Purification. |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
KR101761541B1 (ko) | 2009-10-26 | 2017-07-26 | 네스텍 소시에테아노님 | 항-tnf 약물 및 자가항체의 검출을 위한 검정법 |
AU2011317149B2 (en) | 2010-10-18 | 2015-05-07 | Société des Produits Nestlé S.A. | Methods for determining anti-drug antibody isotypes |
ES2530175T3 (es) | 2011-02-17 | 2015-02-26 | Nestec S.A. | Ensayos para la detección de autoanticuerpos contra fármacos anti-TNF |
CN103649336A (zh) | 2011-05-10 | 2014-03-19 | 雀巢产品技术援助有限公司 | 用于个体化治疗管理的疾病活动性表征方法 |
JP6181646B2 (ja) * | 2011-07-06 | 2017-08-16 | ネステク ソシエテ アノニム | Tnfアルファによる生物学的治療に対する中和自己抗体の検出のためのアッセイ |
EP2786156A2 (en) * | 2011-11-30 | 2014-10-08 | AbbVie Deutschland GmbH & Co KG | Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor |
JP6272788B2 (ja) * | 2012-03-08 | 2018-01-31 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 循環中の免疫複合体を特徴付けるためのマルチプレックス式クロマトグラフィー−イムノアッセイ法 |
US20130295685A1 (en) * | 2012-04-10 | 2013-11-07 | Nestec S.A. | Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies |
US10132736B2 (en) * | 2012-05-24 | 2018-11-20 | Abbvie Inc. | Methods for inspection of protein particles in a liquid beneficial agent |
WO2014046474A2 (ko) * | 2012-09-21 | 2014-03-27 | 가톨릭대학교 산학협력단 | 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물 |
KR101501375B1 (ko) | 2012-09-21 | 2015-03-10 | 가톨릭대학교 산학협력단 | 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물 |
MX358730B (es) | 2012-10-05 | 2018-09-03 | Nestec Sa | Metodos para predecir y monitorear cicatrizacion de la mucosa. |
BR112015012482A2 (pt) * | 2012-11-30 | 2017-07-11 | Nestec Sa | ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos |
EP2954329A1 (en) | 2013-02-05 | 2015-12-16 | Nestec S.A. | Methods of selecting combination therapy for colorectal cancer patients |
EP2997371B1 (en) * | 2013-05-16 | 2018-11-07 | University of Pretoria | A method of diagnosing tuberculosis |
CA2932571A1 (en) | 2013-12-03 | 2015-06-11 | Nestec S.A. | Methods for predicting post-operative recurrence of crohn's disease |
CA2932569A1 (en) | 2013-12-03 | 2015-06-11 | Nestec S.A. | Signaling pathways in tissues from inflammatory bowel disease patients |
WO2015110989A1 (en) | 2014-01-23 | 2015-07-30 | Nestec S.A. | Biomarker panel for assessment of mucosal healing |
WO2015166461A1 (en) | 2014-05-01 | 2015-11-05 | Nestec S.A. | Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels |
MX2017004742A (es) | 2014-10-20 | 2017-07-20 | Nestec Sa | Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos. |
WO2016063223A1 (en) | 2014-10-20 | 2016-04-28 | Nestec S.A. | Methods for predicting clinical outcomes in subjects afflicted with ulcerative colitis |
EP3227685A1 (en) | 2014-12-02 | 2017-10-11 | Nestec S.A. | Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease |
WO2016088104A2 (en) * | 2014-12-05 | 2016-06-09 | Nestec S.A. | Indirect homogeneous mobility shift assays for the detection of biologics in patient samples |
US11085931B2 (en) | 2015-01-09 | 2021-08-10 | W. Health L.P. | Universal assay for determining the quantity of TNFα inhibitory drugs and their corresponding anti-drug-antibodies |
WO2016135707A1 (en) | 2015-02-27 | 2016-09-01 | Nestec S.A. | Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders |
ES2815224T3 (es) | 2015-11-06 | 2021-03-29 | Promise Proteomics | Un método para cuantificar anticuerpos terapéuticos |
EP3165928B1 (en) | 2015-11-06 | 2019-01-09 | Promise Advanced Proteomics | A method for quantifying anti-tnf antibodies |
WO2017201142A1 (en) * | 2016-05-17 | 2017-11-23 | Memorial Sloan Kettering Cancer Center | Treatment of lung adenocarcinoma |
EP3482199A1 (en) * | 2016-07-08 | 2019-05-15 | Atonomics A/S | A universal assay for determining the quantity of therapeutic monoclonal antibodies and their corresponding anti-drug-antibodies in samples |
AU2018349287A1 (en) | 2017-10-10 | 2020-05-07 | Prometheus Biosciences, Inc. | Methods for monitoring vedolizumab treatment |
EP3514541A1 (de) * | 2018-01-17 | 2019-07-24 | Siemens Healthcare Diagnostics Products GmbH | Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors |
EP3781943B1 (en) * | 2018-04-20 | 2022-04-27 | Janssen Biotech, Inc. | Chromatography column qualification in manufacturing methods for producing anti-il12/il23 antibody compositions |
US20230035363A1 (en) * | 2019-03-04 | 2023-02-02 | Amgen Inc. | In vivo reversibility of high molecular weight species |
KR102562006B1 (ko) | 2020-11-09 | 2023-08-02 | 바디텍메드(주) | 항tnf-알파 약물 모니터링을 위한 신속 검출 키트 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5700466A (en) | 1981-09-08 | 1997-12-23 | The Rockefeller University | Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor |
US4459359A (en) | 1981-11-19 | 1984-07-10 | New York Blood Center, Inc. | Sensitive immunoassays of antigens or antibodies sequestered within immune complexes |
US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US4857456A (en) | 1985-04-30 | 1989-08-15 | The Regents Of The University Of California | Assay of Bone morphogenetic protein (BMP) and anti-BMP antibody for the diagnosis of bone disorders |
FR2590674B1 (fr) | 1985-11-25 | 1989-03-03 | Inst Nat Sante Rech Med | Nouveaux reactifs de diagnostic |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
US5223395A (en) | 1988-12-01 | 1993-06-29 | Centocor, Inc. | Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples |
EP0440044A1 (en) | 1990-01-31 | 1991-08-07 | Abbott Laboratories | Avoidance of human anti-mouse antibody interference in in vitro diagnostic testing |
US5094740A (en) | 1990-02-16 | 1992-03-10 | Glycomed, Inc. | Two-dimensional electrophoretic separation of carbohydrates |
GB9028123D0 (en) * | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
US5582998A (en) | 1991-06-19 | 1996-12-10 | Boehringer Ingelheim International Gmbh | Monoclonal antibodies against human TNF-binding protein I (TNF-BP I) and immunoassays therefor |
JPH0566222A (ja) | 1991-09-09 | 1993-03-19 | Tosoh Corp | 物質の分析方法 |
ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
JPH07110331A (ja) * | 1993-09-07 | 1995-04-25 | Wako Pure Chem Ind Ltd | ヒト補体価測定方法及びヒト補体価測定用試薬組成物 |
EP0642021B1 (en) | 1993-09-07 | 2000-11-02 | Wako Pure Chemical Industries Ltd | Process for measuring complement activity and reagent used therefor |
JPH07140144A (ja) | 1993-11-19 | 1995-06-02 | S R L:Kk | アレルゲン特異的IgE抗体の測定方法および抗原抗体複合体の測定方法 |
CA2209172C (en) | 1994-12-28 | 2007-04-10 | University Of Kentucky | Murine monoclonal anti-idiotype antibody 3h1 |
HU230048B1 (hu) * | 1996-02-09 | 2015-06-29 | Abbvie Biotechnology Ltd | Humán TNFalfa-kötő antitestek alkalmazása |
JP3718435B2 (ja) * | 1996-08-12 | 2005-11-24 | 積水化学工業株式会社 | 細胞機能測定用容器及び細胞機能測定方法 |
EP0882984B1 (en) | 1996-08-12 | 2010-10-06 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Containers and kits for the determination of cell functions, and method for the determination thereof |
US6391622B1 (en) | 1997-04-04 | 2002-05-21 | Caliper Technologies Corp. | Closed-loop biochemical analyzers |
US6309888B1 (en) | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
JP4803879B2 (ja) * | 1998-10-31 | 2011-10-26 | アメリカ合衆国 | ヒト化抗−癌腫モノクローナル抗体cc49 |
US6818749B1 (en) * | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
DE19858777B4 (de) * | 1998-12-18 | 2006-07-27 | Delta Biotechnology Ltd. | Verfahren zur teilweisen oder vollständigen Trennung von glykosilierten und nicht-glykosilierten Proteinen |
RU2260422C2 (ru) * | 1999-12-06 | 2005-09-20 | Лео Фарма А/С | АМИНОБЕНЗОФЕНОНЫ КАК ИНГИБИТОРЫ ИЛ-β И ТНФ-α |
US6680209B1 (en) | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
JP2004500063A (ja) | 1999-12-16 | 2004-01-08 | アムジェン インコーポレイテッド | Tnfr/opg様分子およびその使用 |
UA81743C2 (uk) * | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
WO2002071066A1 (en) | 2001-03-02 | 2002-09-12 | Activx Biosciences, Inc. | Protein profiling platform |
US7256257B2 (en) * | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20030040027A1 (en) | 2001-08-16 | 2003-02-27 | Gerd Ritter | Method for determining protein component in a biological sample |
CN1585778A (zh) | 2001-11-12 | 2005-02-23 | 默克专利有限公司 | 修饰的抗-TNFα抗体 |
IL158297A0 (en) | 2001-12-05 | 2004-05-12 | Cangene Corp | Pharmaceutical compositions containing immune globulin and methods for the preparation thereof |
GB0208817D0 (en) | 2002-04-17 | 2002-05-29 | European Molecular Biology Lab Embl | Method for producing monoclonal antibodies |
US20040022792A1 (en) | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
AU2003258036A1 (en) | 2002-08-01 | 2004-02-23 | Wyeth | Methods and reagents relating to inflammation and apoptosis |
US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
US7662569B2 (en) | 2003-04-11 | 2010-02-16 | Cedars-Sinai Medical Center | Methods of assessing Crohn's disease patient phenotype by I2 serologic response |
US8088387B2 (en) * | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
JP4717810B2 (ja) | 2003-06-20 | 2011-07-06 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド | 1型糖尿病と2型糖尿病を識別するためのバイオマーカー |
AU2004262014B2 (en) * | 2003-08-01 | 2010-06-17 | Amgen Inc. | Crystalline tumor necrosis factor receptor 2 polypeptides |
JP2007528868A (ja) | 2003-08-14 | 2007-10-18 | ワイス | 抗ルイスy抗イディオタイプ抗体およびその使用 |
EP1519194A1 (en) | 2003-09-24 | 2005-03-30 | Roche Diagnostics GmbH | Use of gfap for identification of intracerebral hemorrhage |
US20090275496A1 (en) | 2004-05-07 | 2009-11-05 | Peptimmune, Inc. | Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods |
CA2572263A1 (en) | 2004-06-30 | 2006-01-12 | Centocor, Inc. | Detection or measurement of antibodies to antigenic proteins in biological tissues or samples |
US20060253263A1 (en) | 2005-04-11 | 2006-11-09 | Meshkin Brian J | Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy |
EP1902320B1 (en) | 2005-05-20 | 2010-03-10 | Genentech, Inc. | Pretreatment of a biological sample from an autoimmune disease subject |
GB2426581A (en) * | 2005-05-27 | 2006-11-29 | Univ Nottingham | Immunoassay methods |
AU2006272204A1 (en) | 2005-07-21 | 2007-01-25 | Genmab A/S | Potency assays for antibody drug substance binding to an Fc receptor |
US20090162374A1 (en) | 2005-09-14 | 2009-06-25 | Geraghty Daniel E | Specific removal of activated immune cells |
US7542502B2 (en) | 2005-09-27 | 2009-06-02 | Cymer, Inc. | Thermal-expansion tolerant, preionizer electrode for a gas discharge laser |
CA2626859A1 (en) * | 2005-11-08 | 2007-05-18 | Medarex, Inc. | Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy |
JP2007147367A (ja) | 2005-11-25 | 2007-06-14 | Sekisui Chem Co Ltd | サイトカイン産生能の測定方法 |
DE102005057920A1 (de) | 2005-12-02 | 2007-06-28 | Strohner, Pavel, Dr. | Immunoassay zur simultanen immunchemischen Bestimmung eines Analyten (Antigen) und eines gegen den Analyten gerichteten Therapieantikörpers in Proben |
WO2008008349A2 (en) | 2006-07-11 | 2008-01-17 | Drexel University | Methods of quantitatively assessing inflammation with biosensing nanoparticles |
US20080286774A1 (en) | 2007-05-16 | 2008-11-20 | The Regents Of The University Of California | Real-time individualized therapy evaluation |
US20090035216A1 (en) | 2007-08-03 | 2009-02-05 | Biomonitor Aps | Method for determining in vivo biopharmaceutical concentration or bioavailability |
EP2200613B1 (en) * | 2007-09-21 | 2018-09-05 | The Johns Hopkins University | Phenazine derivatives and uses thereof |
EP2240769A1 (en) | 2008-01-15 | 2010-10-20 | Stichting Sanquin Bloedvoorziening | Method and kits for detecting antibodies against therapeutic antibodies |
US20090234202A1 (en) | 2008-03-05 | 2009-09-17 | Goix Philippe J | Method and compositions for highly sensitive detection of molecules |
KR101761541B1 (ko) | 2009-10-26 | 2017-07-26 | 네스텍 소시에테아노님 | 항-tnf 약물 및 자가항체의 검출을 위한 검정법 |
AU2011317149B2 (en) | 2010-10-18 | 2015-05-07 | Société des Produits Nestlé S.A. | Methods for determining anti-drug antibody isotypes |
ES2530175T3 (es) | 2011-02-17 | 2015-02-26 | Nestec S.A. | Ensayos para la detección de autoanticuerpos contra fármacos anti-TNF |
JP6181646B2 (ja) | 2011-07-06 | 2017-08-16 | ネステク ソシエテ アノニム | Tnfアルファによる生物学的治療に対する中和自己抗体の検出のためのアッセイ |
US20130266963A1 (en) | 2011-07-06 | 2013-10-10 | Nestec S.A. | Assay for detecting neutralizing autoantibodies to biologic therapy |
US20130295685A1 (en) | 2012-04-10 | 2013-11-07 | Nestec S.A. | Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies |
US20140051184A1 (en) | 2012-08-15 | 2014-02-20 | Nestec S.A. | Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto |
BR112015012482A2 (pt) | 2012-11-30 | 2017-07-11 | Nestec Sa | ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos |
WO2016088104A2 (en) | 2014-12-05 | 2016-06-09 | Nestec S.A. | Indirect homogeneous mobility shift assays for the detection of biologics in patient samples |
-
2010
- 2010-10-26 KR KR1020127013748A patent/KR101761541B1/ko active IP Right Grant
- 2010-10-26 KR KR1020177020281A patent/KR101881714B1/ko active IP Right Grant
- 2010-10-26 JP JP2012536962A patent/JP5697677B2/ja not_active Expired - Fee Related
- 2010-10-26 MX MX2014002586A patent/MX343328B/es unknown
- 2010-10-26 NZ NZ621655A patent/NZ621655A/en not_active IP Right Cessation
- 2010-10-26 MX MX2012004877A patent/MX2012004877A/es active IP Right Grant
- 2010-10-26 NZ NZ599456A patent/NZ599456A/en not_active IP Right Cessation
- 2010-10-26 CA CA3108458A patent/CA3108458A1/en active Pending
- 2010-10-26 RU RU2015148676A patent/RU2015148676A/ru not_active Application Discontinuation
- 2010-10-26 AU AU2010315547A patent/AU2010315547C1/en not_active Ceased
- 2010-10-26 ES ES10778763T patent/ES2796530T3/es active Active
- 2010-10-26 WO PCT/US2010/054125 patent/WO2011056590A1/en active Application Filing
- 2010-10-26 CA CA2778454A patent/CA2778454C/en active Active
- 2010-10-26 CN CN201510067719.1A patent/CN104634955B/zh not_active Expired - Fee Related
- 2010-10-26 EP EP10778763.2A patent/EP2494352B1/en active Active
- 2010-10-26 RU RU2012121710/15A patent/RU2571489C2/ru not_active IP Right Cessation
- 2010-10-26 BR BR112012009855A patent/BR112012009855A2/pt not_active Application Discontinuation
- 2010-10-26 CN CN201080060442.5A patent/CN102695955B/zh not_active Expired - Fee Related
- 2010-10-26 NZ NZ706187A patent/NZ706187A/en not_active IP Right Cessation
-
2012
- 2012-04-06 US US13/441,727 patent/US8574855B2/en active Active
- 2012-04-19 IL IL219315A patent/IL219315B/en not_active IP Right Cessation
- 2012-05-22 ZA ZA2012/03717A patent/ZA201203717B/en unknown
-
2013
- 2013-10-04 US US14/046,863 patent/US8865417B2/en active Active
-
2014
- 2014-07-21 US US14/336,955 patent/US9506920B2/en active Active
-
2015
- 2015-02-10 JP JP2015024359A patent/JP5878253B2/ja not_active Expired - Fee Related
- 2015-05-28 AU AU2015202899A patent/AU2015202899B2/en not_active Ceased
- 2015-06-23 ZA ZA201504548A patent/ZA201504548B/en unknown
-
2016
- 2016-01-26 JP JP2016012688A patent/JP6082831B2/ja not_active Expired - Fee Related
- 2016-10-19 US US15/297,878 patent/US10386366B2/en active Active
-
2017
- 2017-08-14 AU AU2017213584A patent/AU2017213584B2/en not_active Ceased
-
2018
- 2018-01-04 IL IL256728A patent/IL256728A/en unknown
-
2019
- 2019-07-02 US US16/460,597 patent/US20200018751A1/en not_active Abandoned
- 2019-07-12 AU AU2019205009A patent/AU2019205009A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013508739A5 (ja) | ||
RU2015148676A (ru) | Способы выявления препаратов и аутоантител против tnf | |
JP2014525036A5 (ja) | ||
Sharma et al. | Ultrasensitive direct impedimetric immunosensor for detection of serum HER2 | |
DK2676137T3 (en) | TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS | |
Arola et al. | Specific noncompetitive immunoassay for HT-2 mycotoxin detection | |
JP6181646B2 (ja) | Tnfアルファによる生物学的治療に対する中和自己抗体の検出のためのアッセイ | |
Chen et al. | Nanobody medicated immunoassay for ultrasensitive detection of cancer biomarker alpha-fetoprotein | |
Shahdeo et al. | Label free detection of SARS CoV-2 Receptor Binding Domain (RBD) protein by fabrication of gold nanorods deposited on electrochemical immunosensor (GDEI) | |
WO2010038974A3 (ko) | 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트 | |
BR112013009376A2 (pt) | métodos para determinar isótipos de anticorpos antifármacos | |
Zhu et al. | Combining magnetic nanoparticle with biotinylated nanobodies for rapid and sensitive detection of influenza H3N2 | |
JP2015533788A5 (ja) | ||
JP2014508930A5 (ja) | ||
JP2015529202A5 (ja) | ||
JP2015517801A5 (ja) | ||
JP2015527365A5 (ja) | ||
JP2015527367A5 (ja) | ||
JP2015531768A5 (ja) | ||
Van Stappen et al. | Validation of a sample pretreatment protocol to convert a drug‐sensitive into a drug‐tolerant anti‐infliximab antibody immunoassay | |
JP2010526880A5 (ja) | ||
RU2015125739A (ru) | Тесты детекции нейтрализующих аутоантител для биологической терапии | |
CN111133313A (zh) | 评估生物药物治疗的受试者中的中和性抗体水平的测定及其在个性化医疗中的用途 | |
Yuan et al. | A gel-based visual immunoassay for non-instrumental detection of chloramphenicol in food samples | |
Kriss et al. | Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development |